Enfuvirtide (T-20)

$165.00$485.00

36 residue synthetic peptide that inhibits HIV-1 fusion with CD4 cells. N-terminal acetylated, C-terminal amide. Enfuvirtide is the first in this class to reach market approval. Fusion inhibitors block the last step in the three-step viral entry process consisting of attachment, co-receptor binding and fusion, thereby preventing viral capsid entry into the host cell. Enfuvirtide has a unique mechanism of action and high viral target specificity, and in clinical trials has been shown to exhibit both high efficacy and low toxicity. Enfuvirtide is a peptide mimetic of an essential region within viral envelope glycoprotein gp41 that functions by blocking gp41 structural rearrangements at a transitional pre-fusion conformation.

Clear
Catolog No: N/A Category:

Sequence (One-Letter Code):

Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2

 

Sequence (Three-Letter Code):

Ac-{Tyr}{Thr}{Ser}{Leu}{Ile}{His}{Ser}{Leu}{Ile}{Glu}{Glu}{Ser}{Gln}{Asn}{Gln}{Gln}{Glu}{Lys}{Asn}{Glu}{Gln}{Glu}{Leu}{Leu}{Glu}{Leu}{Asp}{Lys}{Trp}{Ala}{Ser}{Leu}{Trp}{Asn}{Trp}{Phe}-NH2

 

Molecular Weight:

4491.9

 

Purity:
% Peak Area By HPLC ≥ 95%

 

Salt:
TFA Salt

 

Storage:

Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.

 

Note:

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

 

Documents:

MSDS

Amount

1 mg, 5 mg, Other